Home/Pipeline/CT-P55

CT-P55

Psoriasis

Phase 3Active

Key Facts

Indication

Psoriasis

Phase

Phase 3

Status

Active

Company

Celltrion

About Celltrion

Celltrion's mission is to promote patient health by making advanced biologics affordable and accessible globally. It has achieved this by evolving from a contract manufacturer into a vertically integrated powerhouse, becoming the world's leading biosimilar producer with a robust pipeline. Its core strategy leverages massive, FDA/EMA-certified manufacturing capacity, a direct global sales network, and a deep R&D pipeline spanning biosimilars and novel biologics to drive growth and secure long-term market leadership.

View full company profile

Therapeutic Areas

Immunology Oncology Autoimmune Diseases Ophthalmology Respiratory

Other Psoriasis Drugs

Drug	Company	Phase	Status
CYPS317	FibroBiologics	Discovery	Active
PEP Biologic™	Intent Biologics	Unknown	Active
DMT410	Dermata Therapeutics	Preclinical	Exploratory
IL23R program	Acellera	Pre-clinical	Hit-to-Lead
Undisclosed Psoriasis Program	Nepsone	Preclinical	Active
TEM-1657 (Topical)	Temisis	Pre-clinical	Active
TEM-1657 (Oral)	Temisis	Pre-clinical	Active
AIM Platform	Phaim Pharma	Pre-clinical	Active
orismilast	UNION therapeutics	Phase 2	Active
JNJ-77242113	Johnson & Johnson	Phase 3	Active
IL-17A/F Inhibitor (CSPC-2232)	CSPC Pharmaceutical Group Limited	Phase III	Active
Zasocitinib (TAK-279)	Takeda Pharmaceutical	Phase 3	Active